Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

Phase 1 Open-Label Pharmacokinetic, Safety and Tolerability Study of a Single Subcutaneous Dose of Glymera (PB1023) Injection in Subjects With Normal Renal Function and Subjects With Impaired Renal Function

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01478399
• Other study ID #: PB1023-PT-CL-0003
• Status: Completed
• Phase: Phase 1
• First received: November 21, 2011
• Last updated: April 12, 2013
• Start date: December 2011
• Est. completion date: October 2012

Study information

• Verified date: April 2013
• Source: PhaseBio Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Primary objective:

To compare the pharmacokinetic profile of Glymera (PB1023) Injection after a single dose administered by subcutaneous injection to subjects with normal renal function and impaired renal function.

Secondary objectives:

To evaluate the safety and tolerability of Glymera (PB1023) Injection administered as a subcutaneous injection in adult subjects with normal renal function and impaired renal function.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: October 2012
• Est. primary completion date: October 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 79 Years

Eligibility

Inclusion Criteria:

• Males and females age 18 - 79 years of age inclusive.

• BMI 19 - 40 kg/m2.

• Renally Impaired Subjects: In otherwise stable health except for Renal Disease.

• Healthy volunteers must have/be: eGFR as calculated by MDRD of = 80 mL/min, and Matched to renally impaired subjects for age (± 15 years), weight (± 15 kg), and if possible BMI, race and gender.

• Subjects with renal impairment must have 2 separate eGFR that are within 20% of each other and clinically stable for a minimum of 6 months.

• No clinically relevant abnormalities in the results of the laboratory screening or admission evaluation other than those consistent with renal impairment or related disease/disorder in the appropriate subject group as determined by the Investigator.

Exclusion Criteria:

• Currently taking or have taken a GLP -1 agent (e.g., Byetta®, Victoza®) within the past year.

• Subjects who have previously received PB1023.

• Known allergy or serious adverse effect to an approved or investigational GLP-1 receptor analog/agonist.

• Serious Infection within 60 days of admission.

• Donation or loss of greater than 400 mL of blood 56 days prior to enrollment.

• Unstable cardiovascular disease defined as per protocol.

• Clinically significant hepatic dysfunction defined as per protocol.

• Female subjects who are pregnant, trying to become pregnant or lactating.

• Known history of or active alcohol or drug abuse within 12 months prior to Screening or positive alcohol and/or drug screen.

• Positive for Human Immunodeficiency Virus (HIV) antibodies, Hepatitis B surface antigen (HBsAg) or Hepatitis C Virus (HCV) antibodies.

• Participating in any other study at time of screening other than observational studies or have received any other investigational drug or device within 30 days or 5 half-lives prior to dosing or are taking part in a non-drug study which in the opinion of the Investigator would interfere with the outcome of the study.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Renal Insufficiency

Intervention

Drug:
• PB1023 Injection
90 mg Dose

Locations

Country	Name	City	State
United States	New Orleans Center for Clinical Research	Knoxville	Tennessee
United States	Prism Research	Saint Paul	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
PhaseBio Pharmaceuticals Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics	The PK analysis population will consist of subjects that complete the study and have sufficient data for PK analysis. The following parameters will be evaluated: t1/2, AUC(0-inf), Tmax, Cmax, elimination rate constant, CL/F, Vz/F.	Pre-Dose, 1, 4, 8 and 12 hours post-dose, Day 1, 2, 3, 5, 7, 10, 14, 21 and 28	No
Secondary	Safety/Tolerability	Safety and tolerability will be evaluated by analyses of the incidence of adverse events. Vital signs, ECGs and safety laboratory parameters will be presented descriptively.	Screening to Final Visit (Approximately 6 weeks)	Yes